Synergism of Anti-CGRP Monoclonal Antibodies and OnabotulinumtoxinA in the Treatment of Chronic Migraine: A Real-World Retrospective Chart Review

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
1 Online-Ressource.
Language
Englisch

Bibliographic citation
Synergism of Anti-CGRP Monoclonal Antibodies and OnabotulinumtoxinA in the Treatment of Chronic Migraine: A Real-World Retrospective Chart Review ; volume:38 ; number:6 ; day:7 ; month:4 ; year:2024 ; pages:481-491 ; date:6.2024
CNS drugs ; 38, Heft 6 (7.4.2024), 481-491, 6.2024

Creator
Salim, Amira
Hennessy, Elise
Sonneborn, Claire
Hogue, Olivia
Biswas, Sudipa
Mays, MaryAnn
Suneja, Aarushi
Ahmed, Zubair
Mata, Ignacio F.
Contributor
SpringerLink (Online service)

DOI
10.1007/s40263-024-01086-z
URN
urn:nbn:de:101:1-2407252116118.848561939836
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 10:56 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Salim, Amira
  • Hennessy, Elise
  • Sonneborn, Claire
  • Hogue, Olivia
  • Biswas, Sudipa
  • Mays, MaryAnn
  • Suneja, Aarushi
  • Ahmed, Zubair
  • Mata, Ignacio F.
  • SpringerLink (Online service)

Other Objects (12)

CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients

CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients

Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?

Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?

“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies

“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies

Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review

Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review

Interictal burden in migraine patients at the outset of CGRP monoclonal antibody prevention

Interictal burden in migraine patients at the outset of CGRP monoclonal antibody prevention

Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review

Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review

Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?

Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?

CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs

CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs

It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine

It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine

CGRP and migraine: neurogenic inflammation revisited

CGRP and migraine: neurogenic inflammation revisited

Monoclonal Antibodies Targeting CGRP to Treat Vestibular Migraine: A Rapid Systematic Review and Meta-Analysis

Monoclonal Antibodies Targeting CGRP to Treat Vestibular Migraine: A Rapid Systematic Review and Meta-Analysis

Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy

Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy

Related objects